Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. Acquired by Eli Lilly and Company: A Comprehensive Investor Summary

Eli Lilly and Company (NYSE: LLY) will acquire Ventyx Biosciences, Inc. (NASDAQ: VTYX) in a definitive agreement, marking a pivotal moment for the clinical-stage biotechnology firm.

Event Description

Eli Lilly and Company will acquire Ventyx Biosciences, Inc. by purchasing all outstanding Ventyx shares. This acquisition follows Ventyx's strategic review, which began after disappointing clinical trial results for its lead drug candidates. In late 2023, Ventyx discontinued its Phase 2 clinical programs for VTX958 (targeting psoriasis) and VTX002 (targeting ulcerative colitis). These programs ended due to efficacy concerns and a challenging competitive landscape, leading to significant workforce reductions and a strategic review aimed at maximizing shareholder value.

For Eli Lilly, this acquisition represents a strategic move to bolster its drug pipeline, particularly in areas with high unmet medical needs. While Ventyx's primary programs faced setbacks, Lilly likely sees value in Ventyx's remaining assets, such as VTX3232 – an oral drug in development for neurological conditions – and its underlying scientific platforms or talent. This allows Lilly to integrate promising early-stage assets into its robust development infrastructure. Once the transaction closes, Ventyx Biosciences, Inc. will become a wholly-owned subsidiary of Eli Lilly and Company, ceasing to operate as an independent entity or be publicly traded.

Event Date/Timeline

• Agreement Date: Ventyx Biosciences signed the definitive merger agreement with Eli Lilly and Company on January 7, 2024.
• Shareholder Approval: Ventyx shareholders officially approved the transaction on March 3, 2024.
• Anticipated Closing: The acquisition is subject to customary closing conditions, including regulatory approvals (such as antitrust clearance). The companies expect the transaction to close in the second quarter of 2024.

Financial Impact

Eli Lilly will acquire all outstanding Ventyx shares for $15.00 per share in cash, valuing the company's equity at approximately $750 million. Ventyx shareholders will receive this cash payment upon the merger's closing.

• Treatment of Equity Awards: All outstanding Ventyx stock options, restricted stock units (RSUs), and other equity awards will convert into a right to receive cash consideration based on the $15.00 per share price, as outlined in the merger agreement. While the full filing has all the nitty-gritty details on things like vesting acceleration, the main takeaway is that these awards will also convert into cash based on that $15.00 per share price.
• Transaction Expenses: Ventyx Biosciences anticipates incurring certain transaction-related expenses, including legal, financial advisory, and other professional fees, for the merger. Ventyx will cover these expenses before the transaction closes.

Impact Assessment

• Investors: Current Ventyx shareholders will receive $15.00 in cash for each share they own when the merger closes. This eliminates the significant clinical and financial risks associated with Ventyx operating as an independent, publicly traded biotechnology company. The stock will cease trading on NASDAQ after the acquisition closes.
• Ventyx's Pipeline: Eli Lilly will assume control over Ventyx's remaining drug pipeline, including VTX3232. Lilly will then determine the future development strategy and resource allocation for these programs.
• Employees: Ventyx had already implemented significant workforce reductions before the acquisition announcement. While some Ventyx employees may integrate into Eli Lilly's operations, further restructuring or integration efforts are common in such transactions.
• The Company Itself: Ventyx Biosciences, Inc. will become a wholly-owned subsidiary of Eli Lilly and Company and will no longer operate independently or be publicly traded.

Key Takeaways for Investors

• Fixed Payout: Ventyx shareholders will receive a fixed cash payout of $15.00 per share, assuming the deal closes as expected.
• Reduced Risk, Limited Upside: The primary risk for Ventyx investors has shifted from potential clinical trial failures and financial viability to the risk of the acquisition not closing (though this is generally low once shareholder approval is secured). However, the upside potential for Ventyx stock is now capped at the acquisition price.
• Stock Price Behavior: The Ventyx stock price will likely trade very close to the $15.00 acquisition price until the closing date, reflecting the market's confidence in the deal. Any slight discount (known as the "arbitrage spread") typically accounts for the time value of money until closing and the minor risk of the deal falling through.
• Action Required (Potentially): Shareholders do not need to take any immediate action; their brokerage will handle the conversion of shares to cash upon closing. However, investors should monitor for the official closing announcement.
• Focus Shifts: For current Ventyx shareholders, the investment decision is no longer about Ventyx's independent drug development success but purely about the mechanics and certainty of the acquisition.